Azitra (AZTR) said Thursday it has struck a deal to sell about $10.5 million in convertible preferred stock to new and existing healthcare-focused institutional investors.
The deal also includes funding of up to an additional $20.9 million upon exercise of warrants, the clinical-stage firm said. Investors include Stonepine Capital and Nantahala Capital, it added.
Azitra said it plans to use the proceeds for research and development, working capital, and general corporate expenses. It expects to close the transaction March 20.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.